AR124967A1 - Compuesto para el tratamiento de trastornos cognitivos - Google Patents
Compuesto para el tratamiento de trastornos cognitivosInfo
- Publication number
- AR124967A1 AR124967A1 ARP220100405A ARP220100405A AR124967A1 AR 124967 A1 AR124967 A1 AR 124967A1 AR P220100405 A ARP220100405 A AR P220100405A AR P220100405 A ARP220100405 A AR P220100405A AR 124967 A1 AR124967 A1 AR 124967A1
- Authority
- AR
- Argentina
- Prior art keywords
- compound
- subject
- pharmaceutically acceptable
- acceptable salt
- treatment
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 9
- 208000010877 cognitive disease Diseases 0.000 title abstract 4
- 150000003839 salts Chemical class 0.000 abstract 4
- -1 2-oxo-1-pyrrolidinyl triazole Chemical class 0.000 abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 abstract 3
- 102100030701 Synaptic vesicle glycoprotein 2A Human genes 0.000 abstract 2
- 101710084141 Synaptic vesicle glycoprotein 2A Proteins 0.000 abstract 2
- GPGBFZCJDZALPN-QMMMGPOBSA-N (4r)-1-[(5-chloro-1,2,4-triazol-1-yl)methyl]-4-(3,4,5-trifluorophenyl)pyrrolidin-2-one Chemical compound FC1=C(F)C(F)=CC([C@H]2CC(=O)N(CN3C(=NC=N3)Cl)C2)=C1 GPGBFZCJDZALPN-QMMMGPOBSA-N 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Reivindicación 1: Un compuesto que es un 2-oxo-1-pirrolidinil triazol sustituido de fórmula (1) o un isómero o a una sal farmacéuticamente aceptable del mismo, para su uso en el tratamiento de un trastorno cognitivo en un sujeto, en el que el compuesto se administra al sujeto en una cantidad de 0,2 a 5 mg. Reivindicación 5: Un compuesto que es un 2-oxo-1-pirrolidinil triazol sustituido de fórmula (1) o un isómero o a una sal farmacéuticamente aceptable del mismo, para su uso en el tratamiento de un trastorno cognitivo en un sujeto, en el que el compuesto se administra al sujeto en una cantidad que proporciona una ocupación de glicoproteína 2A (SV2A) de vesícula sináptica del 10% al 80% en el nivel mínimo después de una dosis diaria durante al menos 10 días. Reivindicación 9: Una composición farmacéutica que comprende un compuesto que es un 2-oxo-1-pirrolidinil triazol sustituido de fórmula (1) o un isómero o una sal farmacéuticamente aceptable del mismo y uno o más excipientes farmacéuticamente aceptables, para su uso en el tratamiento de un trastorno cognitivo en un sujeto, en la que la composición farmacéutica se administra para liberar en el sujeto una cantidad del compuesto como se define en una cualquiera de las reivindicaciones 1 a 8. Reivindicación 10: El compuesto o composición farmacéutica para su uso de acuerdo con una cualquiera de las reivindicaciones precedentes, en el que el compuesto es (4R)-1-[(5-cloro-1H-1,2,4-triazol-1-il)metil]-4-(3,4,5-trifluorofenil)pirrolidin-2-ona, o una sal farmacéuticamente aceptable del mismo.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP21159595 | 2021-02-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR124967A1 true AR124967A1 (es) | 2023-05-24 |
Family
ID=74797814
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP220100405A AR124967A1 (es) | 2021-02-26 | 2022-02-24 | Compuesto para el tratamiento de trastornos cognitivos |
Country Status (13)
| Country | Link |
|---|---|
| EP (1) | EP4297749A1 (es) |
| JP (1) | JP2024508052A (es) |
| KR (1) | KR20230167032A (es) |
| CN (1) | CN117177746A (es) |
| AR (1) | AR124967A1 (es) |
| AU (1) | AU2022226335A1 (es) |
| BR (1) | BR112023017222A2 (es) |
| CA (1) | CA3209858A1 (es) |
| IL (1) | IL305471A (es) |
| MX (1) | MX2023010044A (es) |
| TW (1) | TW202245754A (es) |
| UY (1) | UY39649A (es) |
| WO (1) | WO2022179873A1 (es) |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8412357D0 (en) | 1984-05-15 | 1984-06-20 | Ucb Sa | Pharmaceutical composition |
| US20120171125A1 (en) * | 2009-08-07 | 2012-07-05 | Ucb Pharma, S.A. | Methods for Enhancing the Cognitive Function |
| WO2014012563A1 (en) * | 2012-07-20 | 2014-01-23 | Ucb Pharma, S.A. | Compounds for enhancing the cognitive function |
| PL3027606T3 (pl) | 2013-08-02 | 2018-07-31 | Ucb Biopharma Sprl | Związki do wzmacniania funkcji poznawczych |
-
2022
- 2022-02-14 KR KR1020237032797A patent/KR20230167032A/ko unknown
- 2022-02-14 AU AU2022226335A patent/AU2022226335A1/en active Pending
- 2022-02-14 CA CA3209858A patent/CA3209858A1/en active Pending
- 2022-02-14 IL IL305471A patent/IL305471A/en unknown
- 2022-02-14 CN CN202280029058.1A patent/CN117177746A/zh active Pending
- 2022-02-14 EP EP22705540.7A patent/EP4297749A1/en active Pending
- 2022-02-14 WO PCT/EP2022/053498 patent/WO2022179873A1/en active Application Filing
- 2022-02-14 JP JP2023576246A patent/JP2024508052A/ja active Pending
- 2022-02-14 BR BR112023017222A patent/BR112023017222A2/pt unknown
- 2022-02-14 MX MX2023010044A patent/MX2023010044A/es unknown
- 2022-02-24 AR ARP220100405A patent/AR124967A1/es unknown
- 2022-02-25 UY UY0001039649A patent/UY39649A/es unknown
- 2022-02-25 TW TW111107164A patent/TW202245754A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TW202245754A (zh) | 2022-12-01 |
| AU2022226335A1 (en) | 2023-09-21 |
| IL305471A (en) | 2023-10-01 |
| WO2022179873A1 (en) | 2022-09-01 |
| UY39649A (es) | 2022-09-30 |
| MX2023010044A (es) | 2023-11-09 |
| EP4297749A1 (en) | 2024-01-03 |
| JP2024508052A (ja) | 2024-02-21 |
| BR112023017222A2 (pt) | 2023-11-21 |
| CN117177746A (zh) | 2023-12-05 |
| KR20230167032A (ko) | 2023-12-07 |
| CA3209858A1 (en) | 2022-09-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69914085T2 (de) | Verwendung von aryl- (oder heteroaryl-) azoylcarbinolderivaten zur behandlung von durch überschuss von substanz p hervorgerufenen beschwerden | |
| Bersani et al. | 5-HT2 antagonist ritanserin in neuroleptic-induced parkinsonism: a double-blind comparison with orphenadrine and placebo | |
| SI3075726T1 (en) | DERIVATIVES OF UREA OR ITS PHARMACOLOGICAL RECRUITABLE SALTS USED AS FORMIL PEPTIDAL RECEPTOR LIKE 1 (FPRL-1) AGONISTS | |
| ES2168471T3 (es) | 2-(5h)-furanonas diaril-5-oxigenadas como inhibidores de la cox-2. | |
| RU2008141374A (ru) | Фармацевтическая композиция, содержащая по крайнер мере один ингибитор ркс и по крайней мере один ингибитор киназы jak3, предназначенная для лечения аутоиммунных нарушений | |
| TNSN04246A1 (fr) | Derives d'heteroarylamides benzocondenses de thienopyridines utiles comme agents therapeutiques, compositions pharmaceutiques les contenant et methodes pour leur utilisation | |
| CA2789014C (en) | Methods and compositions for improving cognitive function | |
| PE20200740A1 (es) | Analogos de benzoazepina como agentes inhibidores de la tirosina cinasa de bruton | |
| JP5409602B2 (ja) | 慢性疼痛の治療におけるジミラセタムの使用 | |
| MX2021010122A (es) | Compuestos de imidazopiridinilo y su uso para el tratamiento de trastornos neurodegenerativos. | |
| MA46342B1 (fr) | Dérivés de chromane, d'isochromane et de dihydroisobenzofurane en tant que modulateurs allostériques négatifs de mglur2, compositions et leur utilisation | |
| MA33166B1 (fr) | Utilisation de dérivés de pyrimidylaminobenzamide pour le traitement de la fibrose | |
| RU2003125274A (ru) | Применение флумазенила в производстве лекарства для лечения алкогольной зависимости | |
| KR20040000446A (ko) | 중간 용량의 ｌｈｒｈ 길항제를 사용한 치매 및 퇴행성신경질환의 치료 | |
| CR20210284A (es) | Pirazoles como modulares de hemoglobina | |
| AR124967A1 (es) | Compuesto para el tratamiento de trastornos cognitivos | |
| AR057575A1 (es) | Metodo para tratar hiperlipidemia | |
| EP0429360B1 (fr) | Inhibition du syndrome d'abstinence | |
| EA202192180A1 (ru) | Ингибитор киназы atr bay 1895344 для применения для лечения гиперпролиферативного заболевания | |
| MA53372B1 (fr) | Pyridopyrimidinones comme inhibiteurs du récepteur h4 de l'histamine | |
| BR112022025099A2 (pt) | Agente profilático ou terapêutico para porfiria | |
| SI3027606T1 (en) | Compounds for strengthening cognitive function | |
| MXPA01010749A (es) | Metodo para tratar la neurodegeneracion. | |
| JP2006188496A (ja) | ｐ３８ＭＡＰキナーゼ阻害剤を有効成分とする掻痒治療剤 | |
| AR122591A1 (es) | Agente profiláctico o terapéutico para porfirias |